TargetBeta
MUC16
mucin 16, cell surface associated · also CA125, FLJ14303, CA-125 · Mucins
2 programs in company-led studies act on MUC16, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Antibody-drug Conjugate GSK5533524 | GlaxoSmithKline | – | phase 1 | 11 running | – | the company's pipeline |
| HWK-016, MUCIN-16-targeted ADCrule | Whitehawk Therapeutics | – | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Endometrial Neoplasms, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2028HWK-016, MUCIN-16-targeted ADC · Whitehawk Therapeutics · phase 1 · NCT07470853
- Feb 6, 2029Antibody-drug Conjugate GSK5533524 · GlaxoSmithKline · phase 1 · NCT07438782
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.